These top ASX 200 shares could rise 50% to 80%

Analysts are predicting these shares to deliver huge returns over the next 12 months.

Key points
  • Telix Pharmaceuticals is making strides in cancer treatment with its approved product, Illuccix, and a promising pipeline targeting multi-billion-dollar markets, suggesting significant growth potential, backed by bullish analyst forecasts.
  • WiseTech Global's robust logistics software, CargoWise, offers sticky revenue and a competitive edge, with the company further expanding through strategic acquisitions, promising considerable upside as per market analysts.
  • Both companies are poised for substantial growth, potentially offering investors returns of 50% to 80% if they meet their ambitious targets over the next year.

The Australian share market traditionally provides investors with an average return of approximately 10% per annum.

While this is good, investors don't have to settle for average. Not when there are ASX 200 shares out there that analysts believe could generate significantly greater returns over the next 12 months.

With that in mind, let's now take a closer look at two ASX 200 shares that analysts believe could rise between 50% and 80% between now and this time next year. They are as follows:

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.

Image source: Getty Images

Telix Pharmaceuticals Ltd (ASX: TLX)

Telix Pharmaceuticals could be an ASX 200 share with the potential to deliver huge returns for investors.

It is a biotechnology company that specialises in molecular imaging and targeted radiation therapies. This is a new frontier in cancer diagnosis and treatment that combines precision medicine with powerful therapeutic technology.

Its flagship product is Illuccix, which is already approved by regulators and generating strong sales in the US for prostate cancer imaging.

But it isn't stopping there. This ASX 200 share is advancing a deep pipeline of new radiopharmaceutical candidates targeting kidney, brain, and other cancers. And with each of these having the potential to open multi-billion-dollar global markets, Telix certainly has a long growth runway if everything goes to plan.

Bell Potter remains very positive on Telix. It has a buy rating and $23.00 price target on its shares, which implies potential upside of greater than 50% from current levels.

WiseTech Global Ltd (ASX: WTC)

Another ASX 200 share that could be undervalued is logistics solutions technology company WiseTech Global.

Its CargoWise software platform supports global supply chains, helping major freight forwarders and logistics companies manage their operations across multiple countries and modes of transport.

Its recurring revenue has proven incredibly sticky in recent years. Once a customer integrates CargoWise, switching providers is complex and costly.

In addition, WiseTech Global continues to expand both organically and through acquisitions, strengthening its product suite and deepening its global reach.

And with profit margins few rivals can match and a strong balance sheet to fund future growth, analysts at Morgans believe that it deserves a premium valuation.

For example, the broker currently has a buy rating and $127.50 price target on its shares. This suggests that upside of 80% is possible for investors over the next 12 months from where they trade today.

Motley Fool contributor James Mickleboro has positions in WiseTech Global. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals and WiseTech Global. The Motley Fool Australia has positions in and has recommended WiseTech Global. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Man looking happy and excited as he looks at his mobile phone.
Growth Shares

Could this ASX 200 share turn $10,000 into $20,000 by 2030?

The company already has an impressive global presence, but I think there's still plenty of room to grow.

Read more »

Two shop workers smiling and looking at a laptop surrounded by plants.
Growth Shares

The ASX's next great growth stock? I've narrowed my shortlist to two

These companies have already made impressive progress, but I think there's still a lot more they could achieve.

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Growth Shares

2 ASX shares highly recommended to buy: Experts

Multiple brokers are excited about these ideas.

Read more »

A couple sits on the bed in their hotel room wearing white robes, with both having seen bad news on their phones.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This business is delivering significant financial growth.

Read more »

Two work colleagues looking at a laptop and discussing something.
Growth Shares

If I could own just one ASX share for the next decade, these 5 would make my shortlist

Let's see which shares made the cut.

Read more »

Watering can pouring water on increasing piles of coins with green plants on them and a piggy bank and coins on the table.
Growth Shares

My $5k bullish growth play: 3 exciting ASX stocks I just bought for retirement

I’m excited by what these stocks could achieve in the future.

Read more »

Hourglass in a hand with white lines and dollar signs.
Growth Shares

2 top ASX shares to buy and hold for the next decade

I think these businesses have a very exciting future.

Read more »

Two smiling colleagues looking at a tablet in a data centre.
Growth Shares

Where I'd invest $10,000 in ASX growth shares

These shares have strong growth outlooks. Let's get to know them better.

Read more »